Oncobiologics, a late-stage biotech developing biosimilars of blockbuster drugs Avastin and Humira, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
Oncobiologics is ready to begin Phase 3 trials for both Avastin and Humira. If approved, the biosimilars would offer a less-expensive version of Roche's Avastin and AbbVie's Humira. Avastin is among the world's top-selling cancer therapies.
The Cranbury, NJ-based company was founded in 2010 and plans to list on the Nasdaq under the symbol ONS. Oncobiologics filed confidentially on November 16, 2015. Jefferies and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
